I n contrast with most primary cutaneous B-cell lymphomas, primary cutaneous large B-cell lymphomas, leg type (PCLBCLs-LT) are often lifethreatening. [1] [2] [3] Owing to their occurrence in elderly patients (many patients aged Ͼ80 years), these lymphomas have often been treated with radiotherapy alone or palliative chemotherapies, resulting in 5-year survival rates around 50%. [1] [2] [3] Recently, the addition of rituximab to the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) (R-CHOP) was found to prolong survival in 60-to 80-year-old patients with nodal diffuse large B-cell lymphomas (DLBCLs). 4, 5 Although this result was not directly applicable to older patients with PCLBCL-LT, it rapidly led to a significant shift in French practice, consisting in using the classic R-CHOP regimen in patients younger than 80 years and in generally good condition, and less intensive combinations of rituximab and polychemotherapies (R-PCTs) in the oldest and/or frailest patients. To our knowledge, such an approach has never been evaluated.
Methods. All consecutive patients registered in the French
Study Group of Cutaneous Lymphomas for a PCLBCL-LT and treated with R-PCT between January 2002 and June 2007 were included in the study. Medical records were reviewed and comprehensive data were collected, including baseline characteristics, type of R-PCT regimen, adverse events, response to therapy, relapse, extracutaneous progression, subsequent therapies, and final status. Follow-up data were collected from referent dermatologists and from general practitioners, when necessary, until the final evaluation period ( January 1 to March 31, 2008). The study was approved by the institutional review board of Reims University Hospital, Reims, France.
Results. Twenty-five patients, aged 44 to 96 years (median age, 76 years), were included in the study (Table) . For 11 cases (1, 2, 3, 5, 6, 9, 10, 12, 21, 24, and 25), preliminary data and short-term outcomes were previously reported. 2 Twenty patients had lesions located on the leg at presentation, whereas 5 had a PCLBCL-LT at sites other than the leg. Seventeen patients (group 1) received R-PCT Abbreviations: ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone; AraC, aracytine; Aϩ, alive with disease; Chlor, chlorambucil; CNS, central nervous system; CR, complete remission; Dϩ, died of lymphoma; D−, died of unrelated cause; MTX, methotrexate; NA, not applicable; PCDLBCL-LT, primary cutaneous diffuse large B-cell lymphoma, leg type; PR, partial remission; R, rituximab; R-CEOP, rituximab combined with cyclophosphamide, epirubicin, vincristine, and prednisone; R-CHOP, rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone; R-COP, rituximab combined with cyclophosphamide, vincristine, and prednisone; R-CP, rituximab combined with cyclophosphamide and prednisone; R-miniCHOP; lower-dose R-CHOP; R-PCT, rituximab combined with polychemotherapy; RX, radiotherapy. as first-line therapy, and 8 (group 2) received R-PCT as second-line therapy for refractory skin lesions (n=5) or visceral dissemination (n = 3) to the central nervous system (case 21), lung and bone (case 22), or bone marrow and mesenteric nodes (case 16). The R-PCT was R-ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) in 1 case, a standard R-CHOP regimen in 14 cases, an R-CHOP regimen with lower doses (R-miniCHOP) in 7 cases, and a less intensive R-PCT without anthracycline in 4 cases.
All 17 patients in group 1 and 6 of 8 in group 2 achieved a complete response, but 10 experienced relapse in the skin (n=8), the skin and lymph nodes (n=1), or the central nervous system (n = 1). Four patients had multiple successive cutaneous relapses. Treatment of relapses included surgery (1 case), radiotherapy (4 cases), rituximab (1 case), ibritumomab tiuxetan (1 case), and/or various chemotherapies (4 cases). No patient was lost to follow-up. After a 33-month median follow-up, 20 patients were alive (including 13 in complete remission), 3 had died of lymphoma, and 2 had died of unrelated causes. The 3-year disease-specific survival rate was 87%.
Nine patients (36%) had at least 1 grade 3 or higher adverse event, including grade 3 (n=2) or grade 4 (n=5) neutropenia, grade 4 thrombocytopenia (n = 1), grade 4 neutropenic sepsis (n=1), grade 3 cardiac failure (n=1), grade 3 pneumonia (n = 1), and grade 3 venous thrombosis (n=1; this patient had a catheter). One patient died of neutropenic septicemia.
These 25 patients treated with R-PCT were compared with a historic series of 47 patients with PCLBCL-LT who received other therapies only, as detailed in a previous study. 2 The 2 groups did not differ by classic prognostic factors, 2 including age (median ages, 76 vs 78 years) (P=.30), location of skin lesions, clinical stage at diagnosis, performance status, or lactic dehydrogenase level. However, the percentage of patients who achieved a complete response (92% vs 64%) (P=.01) and the 3-year specific survival rates (87% vs 50%) (P= .004) were much higher in patients treated with R-PCT.
Comment. We report for the first time to our knowledge a complete response rate greater than 90% and a 3-year survival rate greater than 80% in patients with PCLBCL-LT. Despite the retrospective design of the study, these results and the comparison with a historic series of patients treated earlier with other therapies only strongly suggest that the prognosis of these lifethreatening lymphomas may be dramatically improved by the use of age-adapted R-PCT. Response and survival rates in our patients were higher than those reported in elderly patients with DLBCL treated with standard R-CHOP, 4, 5 suggesting that PCLBCL-LT could in fact be less aggressive than their systemic counterparts. Patients older than 80 years (n = 9; 36%) and those with a poor general condition received less-intensive R-PCT with overall favorable results. Main adverse events in the entire series were neutropenia and consecutive infections, suggesting that granulocyte-colony stimulating factor should be systematically used when treating PCLBCL-LT with R-PCT, as recommended in at-risk elderly patients with DLBCL. 6 Recurrences were frequent but were of-ten limited to the skin and were responsive to subsequent treatments. These data provide a basis for prospective clinical trials. Further studies could compare standard R-CHOP to less intensive R-PCT and/or investigate the optimal number of R-PCT cycles and the role of a maintenance therapy with rituximab to prevent recurrences.
